Ozempic maker Novo Nordisk suffers share meltdown
At the summit in June 2024, Novo was worth $ 615 billion, but his shares were concerned about the investor company’s ability to navigate in the experimental drug pipeline and challenges in the US market.
Angelo Meda, a portfolio manager and chairman of the stock at Banor Sim in Milan, a small Novo shares, said, “The stock went to one of the biggest disappointment of its market lover.”
“The biggest concern is the illegal channel that removes the market share – something difficult to measure. Trust will take time to rebuild.”
New CEO is an inside
Dousdar, an Iranian born in the United States in the United States, joined Novo in 1992 and will play a new role on August 7.
Novo said that he was currently working as the Vice President of International Operations, a role he took after he directed the company’s work in the Middle East and then in Southeast Asia.
Dousdar, investors and analysts in a call, “We need to increase the sense of urgency and to perform differently,” he said.
Novo was shot by imitators of Wegovy and Özempik GLP-1 drugs for diabetes for weight loss.Credit: Bloomberg
“The arrival of the announcement immediately after the guidance update makes the task even more open.”
Some analysts and investors argued that Novo had to choose a person with an American or the next CEO in the USA. Novo lost the advantage of the US rival Eli Lilly in the USA in the USA.
According to investors and analysts, the most urgent difficulty of the new chief manager is to revive Novo’s performance in the United States, the largest market they are most profitable.
Novo launched the weight loss medication Wegovy about two and a half years before Eli Lilly’s Zepbound. However, Zepbound recipes exceeded Wegovy’s more than 100,000 per week this year.
Loading
In May, Novo said that after the US Food and Pharmaceutical Administration entered into force on May 22 after the Wegovy leaned on compound copies, it was expected to pass into branded treatments, most of the US patients using compound GLP-1 drugs.
“Unfortunately, our last market research shows that this hasn’t happened,” the Chief Financial Affairs Manager Karsten Munk Knudsen called on Tuesday with analysts. One million or more US patients still use the compound GLP-1.
Novo added the US Operations David Moore to the call, accelerating the US FDA dialogue to limit the illegal unification of drugs.
“The compound continues to be a problem we need to discuss, Mo said Moore.
Reuters
In the Business Briefing Bulletin, great stories offer special scope and expert opinion. Sign up for getting every morning on weekdays.
